CD163

Chr 12

CD163 molecule

Also known as: M130, MM130, SCARI1

The CD163 protein functions as an acute phase-regulated receptor on macrophages that clears hemoglobin/haptoglobin complexes through endocytosis, protecting tissues from free hemoglobin-mediated oxidative damage and facilitating iron recycling. Mutations cause autosomal recessive macrophage activation syndrome and hemophagocytic lymphohistiocytosis, typically presenting in early childhood with severe inflammatory episodes. The gene is highly constrained against loss-of-function variants (LOEUF 0.44), indicating intolerance to protein-disrupting mutations.

Summary from RefSeq, UniProt
Research Assistant →
12
Active trials
886
Pubs (1 yr)
46
P/LP submissions
0%
P/LP missense
0.44
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryCD163
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.30) despite low pLI — interpret in context.
📋
ClinVar Variants
45 unique Pathogenic / Likely Pathogenic· 114 VUS of 195 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint
0.44LOEUF
pLI 0.001
Z-score 4.95
OE 0.30 (0.200.44)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint
2.51Z-score
OE missense 0.72 (0.670.78)
455 obs / 632.6 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios
LoF OE0.30 (0.200.44)
00.351.4
Missense OE0.72 (0.670.78)
00.61.4
Synonymous OE0.97
01.21.6
LoF obs/exp: 17 / 57.6Missense obs/exp: 455 / 632.6Syn Z: 0.33
DN
0.6840th %ile
GOF
0.7030th %ile
LOF
0.2774th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

195 submitted variants in ClinVar

Classification Summary

Pathogenic43
Likely Pathogenic2
VUS114
Likely Benign9
Benign10
43
Pathogenic
2
Likely Pathogenic
114
VUS
9
Likely Benign
10
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
43
0
43
Likely Pathogenic
0
0
2
0
2
VUS
0
104
9
1
114
Likely Benign
0
7
0
2
9
Benign
0
4
1
5
10
Total0115558178

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

CD163 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Time Restricted EatingObesityWeight Loss

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

RECRUITING
NCT05114798Phase NAUniversity of Illinois at ChicagoStarted 2022-05-17
Time restricted eatingCalorie Restriction
HealthyObesity

A Study of Adipose Tissue in Adaptive Responses to Exercise

ACTIVE NOT RECRUITING
NCT06053125Phase NAMayo ClinicStarted 2023-11-09
Adipose Tissue BiopsyExercise
Chronic Kidney Diseases

Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation

RECRUITING
NCT06560801Phase PHASE4University of Erlangen-Nürnberg Medical SchoolStarted 2023-07-28
Dapagliflozin 10mg Tab
Environmental Enteric Dysfunction (EED)Stunting

Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan

RECRUITING
NCT07207434Phase PHASE2Aga Khan UniversityStarted 2025-08-30
Oral VancomycinVE818Placebo
Crohn Disease (CD)

The Microbial Impact on Intestinal Fibrosis and the Associated Immune Microenvironment in Crohn's Disease

NOT YET RECRUITING
NCT06720961IRCCS San RaffaeleStarted 2025-04
Collection of surgical specimenCollection of stool sample
Environmental Enteric Dysfunction

Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh

ENROLLING BY INVITATION
NCT06817031Phase PHASE2International Centre for Diarrhoeal Disease Research, BangladeshStarted 2025-04-20
VE818PlaceboOral Vancomycin
Obstructive Sleep Apnea-Hypopnea SyndromeAnxiety DisordersDepressive Disorders

EGR2 and NLRP3 Pathways in Obstructive Sleep Apnea-Related Cognitive and Mood Disorders

RECRUITING
NCT07120711Xinhua Hospital, Shanghai Jiao Tong University School of MedicineStarted 2025-07-01
EGR2/NLRP3 pathway activityfatty tissue
Malnutrition PregnancyMalnutrition in ChildrenMalnutrition (Calorie)

Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories

RECRUITING
NCT07195006University of ZimbabweStarted 2025-01-27
Malnutrition in pregnancy as exposurePoor WASH living conditions as exposure
HealthyHealthy Nutrition

The BEGIN Study Bifidobacterium Infantis to Newborns: Effects of Modulating the Gut Microbial Composition on Growth, Immune Function and Inflammatory Conditions - a Randomized Placebo-controlled Double-blinded Intervention Trial

RECRUITING
NCT06452199Phase NAUniversity of AarhusStarted 2024-06-10
B. infantisPlacebo
Oral LeukoplakiaOral Leukoplakia of TongueOral Leukoplakia of Gingiva

Prediction of Malignant Transformation of Oral Leukoplakia Using a MAGE-A-based Immunoscore

RECRUITING
NCT03975322University of Erlangen-Nürnberg Medical SchoolStarted 2019-12-01
Environmental Enteric Dysfunction (EED)

Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II)

RECRUITING
NCT07134790Phase PHASE2University GhentStarted 2025-07-30
VE818PlaceboOral Vancomycin
Psoriasis VulgarisPsoriasisSkin Diseases

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

ACTIVE NOT RECRUITING
NCT05185258Phase PHASE4Aarhus University HospitalStarted 2022-02-16
EnstilarPlacebo-vehicle
Clinical Literature
Open Research Assistant →
Full-Text Mentions
NLP-detected gene mentions in article bodies · via PubTator3
PubTator3
Top 5 full-text resultsSearch PubTator3 ↗